Is Bloom Energy The Best Stock to Buy Now?
Shares of energy startup Bloom Energy (NYSE:BE) have advanced by…
Sell
15
AFMDQ Quote, Financials, Valuation and Earnings
Last price:
$0.0000
Seasonality move
:
2.05%
Day range:
$0.0003 - $0.0020
52-week range:
$0.0000 - $1.5400
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.02x
P/B ratio:
0.00x
Volume:
55.8K
Avg. volume:
13.4K
1-year change:
-99.97%
Market cap:
$4.9K
Revenue:
--
EPS (TTM):
--
Analysts' Opinion
-
Consensus RatingNo consensus rating exists at this time due to lack of analyst coverage.
-
Price Target UpsideNo price target exists because of limited analyst coverage.
-
Price Target DownsideSimilarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.
Fair Value
-
According to the consensus of 0 analysts, Affimed NV has 130858.1% upside to fair value with a price target of -- per share.
AFMDQ vs. S&P 500
-
Over the past 5 trading days, Affimed NV has overperformed the S&P 500 by 199.69% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Affimed NV does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Affimed NV revenues have been falling on a year-over-year basis for 8 quarters in a row. In the most recent quarter Affimed NV reported revenues of --.
Earnings Growth
-
Affimed NV earnings have been falling on a year-over-year basis for 3 quarters in a row. In the most recent quarter Affimed NV reported earnings per share of --.
Enterprise value:
-12.5M
EV / Invested capital:
--
Price / LTM sales:
0.02x
EV / EBIT:
--
EV / Revenue:
-13.19x
PEG ratio (5yr expected):
0.00x
EV / Free cash flow:
0.15x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | $43.6M | $19.9M | $948.4K | $2.1M | $170.3K | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$90.6M | -$125.6M | -$80.2M | -$27.1M | -$15.7M | |
| EBITDA | -$89M | -$122.4M | -$76.4M | -$26.3M | -$15.2M | |
| Diluted EPS | -$0.62 | -$0.85 | -$3.64 | -$0.18 | -$1.03 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $118.9M | $235.6M | $225.9M | $113.1M | $36.2M | |
| Total Assets | $126.6M | $255.4M | $231.6M | $127.5M | $44.6M | |
| Current Liabilities | $53M | $76.8M | $40M | $30.6M | $18.7M | |
| Total Liabilities | $71.4M | $100.2M | $54.2M | $46.6M | $25.4M | |
| Total Equity | $55.1M | $155.1M | $177.4M | $80.9M | $19.2M | |
| Total Debt | $1.5M | $12.8M | $13.5M | $16.1M | $7.9M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$103.9M | -$124.8M | -$82.8M | -$19.8M | -$13.1M | |
| Cash From Investing | $907.6K | -$38.5M | $22.1M | -$40.7M | $7.6M | |
| Cash From Financing | $117.3M | -$4.7M | $876.5K | -$1.7M | $1.4M | |
| Free Cash Flow | -$106.8M | -$128.8M | -$83.4M | -$23.3M | -$13.1M | |
AFMDQ
Sector
Market Cap
$4.9K
$27.9M
Price % of 52-Week High
0.02%
51.04%
Dividend Yield
0%
0%
Shareholder Yield
--
-1.49%
1-Year Price Total Return
-99.98%
-16.66%
Beta (5-Year)
1.610
0.516
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$0.0006
200-day SMA
Sell
Level
$0.2014
Bollinger Bands (100)
Sell
Level
-0.0082 - 0.0118
Chaikin Money Flow
Sell
Level
-484.6M
20-day SMA
Sell
Level
$0.0029
Relative Strength Index (RSI14)
Sell
Level
48.1288
ADX Line
Buy
Level
86.8763
Williams %R
Buy
Level
-85.0425
50-day SMA
Sell
Level
$0.0017
MACD (12, 26)
Sell
Level
-0.0007
25-day Aroon Oscillator
Sell
Level
-56
On Balance Volume
Neutral
Level
897.6M
Financial Scores
--
Altman Z-Score
(Annual)
Level (--)
--
CA Score
(Annual)
Level (--)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (1)
--
Ohlson Score
Level (--)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Affimed NV is a clinical-stage immuno-oncology company, which engages in the discovery and development of cancer immunotherapies. The company’s proprietary ROCK platform enables a tumor-targeted approach to recognize and kill a range of hematologic and solid tumors, enabling a broad pipeline of wholly-owned and partnered single agent and combination therapy programs. It operates through the Germany and USA geographical segments. The company was founded in 2000 and is headquartered in Mannheim, Germany.
Stock Forecast FAQ
In the current month, AFMDQ has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The AFMDQ average analyst price target in the past 3 months is --.
-
Where Will Affimed NV Stock Be In 1 Year?
According to analysts, the consensus estimate is that Affimed NV share price will rise to -- per share over the next 12 months.
-
What Do Analysts Say About Affimed NV?
Analysts are divided on their view about Affimed NV share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Affimed NV is a Sell and believe this share price will drop from its current level to --.
-
What Is Affimed NV's Price Target?
The price target for Affimed NV over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is AFMDQ A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Affimed NV is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of AFMDQ?
You can purchase shares of Affimed NV via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Affimed NV shares.
-
What Is The Affimed NV Share Price Today?
Affimed NV was last trading at $0.0000 per share. This represents the most recent stock quote for Affimed NV. Yesterday, Affimed NV closed at $0.0003 per share.
-
How To Buy Affimed NV Stock Online?
In order to purchase Affimed NV stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Related Companies
Get AFMDQ Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
AFMDQ
Sector
P/E ratio
--
23.85x
PEG ratio
0.00x
-0.01x
P/B ratio
0.00x
1.81x
Price / LTM sales
0.02x
1.58x
Growth Metrics
AFMDQ
Sector
Revenue growth
--
4.62%
Earnings growth
--
10.5%
Revenue (5-year growth)
--
6.5%
Earnings forecast
-$0.55
-$0.21
Profitability
AFMDQ
Sector
Profitability FY 2025
--
$3.6M
Return on invested capital
--
-31.87%
Return on assets
--
-28.18%
Return on equity
--
-37.63%
Earnings Date
Last Earnings Date
Jun
9
Next Earnings Date
Dec
22
Estimated Next Earnings Date
Mar
23
Balance Sheet
AFMDQ
Sector
Total cash
--
$26.4M
Short term investments
--
$25.7M
Total assets
--
$76.9M
Long term debt
--
$3.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Berkshire Hathaway Stock Undervalued?
Berkshire Hathaway (NYSE:BRK.A,BRK.B) has undershot the market this year, returning…
Is Oracle Stock Undervalued?
Shares of Oracle (NYSE:ORCL) rocketed higher earlier this year when…
Stock Ideas
Buy
54
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 62x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
57
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 38x
Alerts
Sell
1
LW alert for Dec 20
Lamb Weston Holdings, Inc. [LW] is down 25.96% over the past day.
Buy
54
BMRN alert for Dec 20
BioMarin Pharmaceutical, Inc. [BMRN] is up 17.79% over the past day.
Buy
82
RKLB alert for Dec 20
Rocket Lab Corp. [RKLB] is up 17.72% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
